Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Jeffrey Cohen MD

Jeffrey A. Cohen MD

Hazel Prior Hostetler Endowed Chair; Professor, Cleveland Clinic Lerner College of Medicine; Director, Experimental Therapeutics, Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio

Dr. Cohen is Professor of Neurology in the Cleveland Clinic Lerner College of Medicine and holds the Hazel Prior Hostetler Endowed Chair.  He received a BA from Connecticut College in 1976 and MD from the University of Chicago School of Medicine in 1980.  He completed a Neurology Residency in 1984 then a Post-doctoral Research Fellowship in Neuroimmunology in 1987, both at the University of Pennsylvania.  Dr. Cohen has worked at the Mellen MS Center at the Cleveland Clinic since 1994 and was Director 2014-2017.  He currently is Director of the Experimental Therapeutics Program, the Clinical Neuroimmunology Fellowship, and the MS Academic Coordinating Center.  Dr. Cohen has published extensively on clinical, immunologic, imaging, and therapeutic aspects of MS.  He has had a leadership role in a large number of clinical trials of potential therapies for MS, translational studies, studies to validate outcome measures, and observational studies. He recently served as Chair of the International Advisory Committee on Clinical Trials in MS and Co-Chair of the International Panel on Diagnosis of Multiple Sclerosis which developed the 2017 McDonald Diagnostic Criteria.  He currently is President of ACTRIMS.


Dr. Cohen reports personal compensation for consulting for Biogen, Bristol-Myers Squibb, Convelo, Genentech, Janssen, NervGen, Novartis, and PSI; speaking for H3 Communications; and serving as an Editor of Multiple Sclerosis Journal.

Recent Contributions to PracticeUpdate:

  1. Smoking Cessation May Improve Disability Progression in MS